Imagine developing a drug that extends life, only to discover later that it works in one sex but actually harms the other sex. That is surprisingly common in longevity research. Here’s the problem: a 2023 review of 72 mouse studies testing drugs for their effects on lifespan or healthspan found that one in three used only males. Just over a third included both sexes.1
Moving from mice to people does not automatically close that gap. A review of human drug trials published in two clinical pharmacology journals found that one in five trials in 2020 and 2021 enrolled only men.2…
